MitoKor, Inc. provided discovery and diagnostic development of mitochondrial medicine. It was a biotechnology company focused on the research and development of drugs for the treatment of major diseases and conditions associated with mitochondrial dysfunction. The company was headquartered in San Diego, CA

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

PAEAN Biotechnology, Inc. is a company headquartered in Daejeon, the South Korea, that provides biotechnology research and development services. It was founded in 2013 by Gyu-Beom Han, who has been the CEO since the inception date.

BASF AB supplies raw materials to paper, chemicals, and construction industries. Its products include construction chemical, crop protection products, dispersions and pigments, plastics, polyurethane systems and coating products. The company was founded in 1953 and is headquartered in Göteborg, Sweden.

Minovia Therapeutics Ltd. is a company headquartered in Tirat Carmel, Israel. The firm develops mitochondrial cell therapies. It was founded in 2012 by Uriel Halavee, Ephraim Aharonson and Natalie Yivgi-Ohana. Natalie Yivgi-Ohana has been the CEO since the company founding.\nThe company says this about itself: Minovia Therapeutics is a clinical stage company and the first to use a cell therapy approach to treat patients affected with mitochondrial diseases using the Mitochondrial Augmentation Technology (MAT) platform. MAT is being developed as a robust and scalable therapeutic platform targeting the root cause of diseases caused by mitochondrial dysfunction. In MAT, patients? hematopoietic stem and progenitor cells are enriched with healthy mitochondria isolated from an allogeneic or syngeneic source.

Edison is a world leader in the discovery and development of redox drugs. The company has obtained orphan designation in both the United States and Europe for its first drug candidate, EPI-743 . Vincerinone is now in phase 2 clinical development. It is being evaluated in multiple clinical indications where defects in the mitochondrial proteins and redox control have been well characterized.

NuSirt Sciences is a biotechnology company focused on developing products targeting metabolic diseases associated with over-nutrition such as obesity, diabetes, and inflammatory stress. The company has developed a breakthrough technology platform that combines natural compounds with various pharmaceutical agents. NuSirts first product, NS-0100, uses NuSirts platform technology to combine the natural product leucine with a very low dose of metformin for the treatment of type II diabetes. Although, metformin is the gold standard in the treatment of early-type II diabetes many patients can not tolerate the adverse gastrointestinal side effects metformin can cause in some patients. The company is currently testing varying doses of NS-0100 in Phase 2 clinical study to find the most efficacious dose of this new combination. If NuSirts clinical trials are successful NS-0100 may offer patients a viable alternative to metformin. NuSirt has filed eleven patent applications (two of which have been issued) and completed four clinical and numerous pre-clinical studies based on the patented technologies.

Established in 1945, Amorepacific is Korea’s No.1 beauty company and a blue-chip corporation. Amorepacific owns nearly 30 well-known brands and has been developing rapidly worldwide. Amorepacific pays great attention to product research and development through research centers located in Korea, France, Japan and Shanghai, to develop premium and high quality skincare and cosmetics products. The Group chose Hong Kong as a strategic bridgehead for the expansion of its presence across the Greater China region and the rest of the world. Two flagship brands - LANEIGE and Sulwhasoo, were introduced in Hong Kong in 2002 and 2004 respectively. The eponymous luxury brand – AMOREPACIFIC, was introduced in Hong Kong in 2014. In 2015, ETUDE HOUSE, a playful cosmetics brand, made its debut in the territory. In 2018, the Company set foot in the personal care product market, introducing the Group’s legendary hair care brand ‘Ryo’ into Hong Kong.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Amazentis SA is a company headquartered in Lausanne, Switzerland. The firm engages in research and development of life sciences. It was founded in 2007 by Patrick Aebischer, Chris Rinsch and Pierre Landolt. Chris Rinsch has been the CEO since the company founding.\nThe company says this about itself: Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals including Nature Medicine (doi:10.1038/nm.4132), Nature Metabolism (doi: 10.1038/s42255-019-0073-4), JAMA Network Open (doi:10.1001/jamanetworkopen.2021.44279) and European Journal of Clinical Nutrition (https://doi.org/10.1038/s41430-021-00950-1). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular health.

Commonwealth Scientific & Industrial Research Organisation provides scientific and industrial research services. It plays a role in collaboration within the Australian national innovation system and as an advisor to government, industry and the community. The company was founded in 1916 and is headquartered in Canberra, Australia.

Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

An internationally-recognized model of excellence in biomedical research and known for its multidisciplinary training centre, the IRCM brings together 33 research units grouped together into five research divisions and houses four specialized clinics as well as a research centre of rare and genetic diseases in adults. Equipped with state-of-the-art technology, our research teams are dedicated to basic and clinical research and contribute significantly to scientific progress. The IRCM is affiliated with the Université de Montréal and associated with McGill University.see less

Khondrion BV is a company headquartered in Nijmegen, the Netherlands, that manufactures and markets pharmaceutical products. It was founded in 2012 by Jan Smeitink, who has been the CEO since that date.\nThe company says this about itself: Khondrion is a clinical stage biopharmaceutical company developing therapies for patients with inherited mitochondrial diseases. Based on proprietary science and a deep biological understanding of mitochondrial dysfunction, the company is advancing its lead drug candidate sonlicromanol. Sonlicromanol is a first-in-class, oral small molecule targeting key underlying mechanisms of mitochondrial disease based on its uniquely differentiated triple mode of action: reductive distress modulation to help restore the cell?s metabolism, oxidative distress modulation preventing ferroptotic cell death, and selective mPGES-1 inhibition resulting in anti-inflammatory effects.